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Amniotic ﬂuid (AF) was described as a potential source of mesenchymal stem cells (MSCs) for biomedicine purposes. Therefore,
evaluation of alternative cryoprotectants and freezing protocols capable to maintain the viability and stemness of these cells after
cooling is still needed. AF stem cells (AFSCs) were tested for diﬀerent freezing methods and cryoprotectants. Cell viability, gene
expression, surface markers, and plasticity were evaluated after thawing. AFSCs expressed undiﬀerentiated genes Oct4 and Nanog;
presented typical markers (CD29, CD44, CD90, and CD105) and were able to diﬀerentiate into mesenchymal lineages. All tested
cryoprotectants preserved the features of AFSCs however, variations in cell viability were observed. In this concern, dimethyl
sulfoxide (Me2SO) showed the best results. The freezing protocols tested did not promote signiﬁcant changes in the AFSCs
viability. Time programmed and nonprogrammed freezing methods could be used for successful AFSCs cryopreservation for 6
months. Although tested cryoprotectants maintained undiﬀerentiated gene expression, typical markers, and plasticity of AFSCs,
only Me2SO and glycerol presented workable viability ratios.
1.Introduction
Knowledge about cryopreservation protocols that keep un-
changedoriginalstemcellspropertiesisextremelyimportant
for cell culture and stem cells storage. For prolonged storage,
cells are usually slowly frozen and stored at −196◦Ci nl i q u i d
nitrogen. Slowly cooling avoids intracellular ice buildup,
which can cause rupture of the cell membrane. Nevertheless,
it can result in dehydration of the cells by formation of extra-
cellular ice. To prevent this, an ideal cooling rate should be
chosen and a cryoprotectant added. The general properties
required for the cryoprotectant compounds are that they
have low molecular weight, are nontoxic, and have low costs
[1, 2].
Cryoprotectants are divided into two main classes: intra-
cellular agents, which penetrate inside the cells preventing
ice crystals formation and membrane rupture (i.e., dimethyl
sulfoxide (Me2SO), glycerol, and ethylene glycol) and extra-
cellular compounds that do not penetrate in cell membrane
and act by reducing the hyperosmotic eﬀect present in freez-
ing procedure. Among them are sucrose, trehalose, dextrose,
and polyvinylpyrrolidone [3].
The main commonly used cryoprotectant, dimethylsul-
foxide (Me2SO), provides a high rate of postfreezing cell sur-
vival, but several groups show that it can promote stem-cell
diﬀerentiation in neuronal lineage and also presents cyto-
toxicity at room temperature [4–8]. There are few alterna-
tive cryoprotectants to Me2SO use at the moment. Other
substances such as glycerol, sucrose, or trehalose do not
present cytotoxicity but still need to be more evaluated as
cryoprotectants for mesenchymal stem cells (MSCs).2 Journal of Biomedicine and Biotechnology
MSCs are multipotent cells capable to diﬀerentiate into
several lineages in vitro. They are described as adherent cells
with ﬁbroblast-like morphology and able to diﬀerentiate
in mesenchymal lineages such as chondrogenic, osteogenic,
myogenic, and adipogenic [9]. In other studies it was dem-
onstrated that MSCs, under proper conditions, are also
capable of diﬀerentiating into nonmesenchymal lineages as
hepatocyteandneuronal-like cells[10,11].Humanamniotic
ﬂuid (AF), a dynamic and complex mixture that reﬂects
the physiological status of the developing fetus, was related
recently as an alternative source of MSCs [12].
AF obtained in second trimester of pregnancy is com-
p o s e do faw i d ev a r i e t yo fc e l l sd e r i v e dm a i n l yf r o mf e t a l
exfoliation during development. Among these cells, some
have adherent properties and express undiﬀerentiated mark-
ers such as Oct-4 gene. These cells are also capable of self-
renewal and diﬀerentiation into mesodermal tissues in cul-
ture. They have been classiﬁed as amniotic ﬂuid mesenchy-
mal stem cells (AFSCs) [13–15].
Here we evaluated the eﬀects of two cryopreservation
methods(time-programmedandnonprogrammedtempera-
ture freezing) and four distinct cryoprotectants in the AFSCs
viability and main characteristics maintenance after liquid
nitrogen storage.
2.MaterialsandMethods
All culture media and chemical reagents were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine
serum and antibiotics were purchased from Invitrogen
(Carlsbad, CA, USA). Primers were from IDT (Integrated
DNA Technologies, San Diego, CA, USA). Ntera-2.c1D1
(human pluripotent testicular carcinoma/ATCC CRL-1973)
was purchased from American Cell Type Collection (Manas-
sas, VA, USA).
2.1. Human Amniotic Fluid Stem Cells. Human amniotic ﬂu-
id samples were collected during scheduled amniocentesis at
12 to 18 weeks of gestation for diagnosis reasons. Collection
procedure was performed under aseptic conditions using
a 22-gauge needle and under ultrasonographic control.
All samples were obtained after signed informed consent.
The protocol was approved by the Ethics Committee from
University of Sao Paulo School of Medicine, Brazil (no.:
0410-09).
After collection, each sample was centrifuged at 450 × g
for 10min at room temperature. The resulting pellets were
washed with PBS (phosphate buﬀer saline), suspended in
minimal essential medium—α-modiﬁcation (α-MEM), sup-
plemented with 20% fetal bovine serum, 100UI/mL peni-
cillin, 100μg/mL streptomycin, and maintained in incubator
with5%CO2 atmosphere at 37◦C for approximately 12 days,
when the ﬁrst colonies appeared. The medium was changed
every 3-4 days.
2.2. Growth Curve and Doubling Time. For growth curve,
AFSCs were seeded in 48-well plates (Corning, USA), and
cultivated for 12 days in a platting density of 5,000 cells/cm2.
Cell number was assessed daily in triplicate by trypan blue
staining in hemocytometer (Optik Labor, Friedrichshofen,
Germany) counting. Cell population doubling time was
calculated by the following formula: t = 3,3 × log(Y/Y0),
where: T: time (hours), Y:ﬁ n a lc e l ln u m b e r ,a n dY0: starting
cell number.
2.3. AFSC Undiﬀerentiated Gene Expression by RT-PCR.
To evaluate undiﬀerentiated state of AFSCs, speciﬁc gene
expressions were determined: Oct-4 and Nanog. Total RNA
was extracted using Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Purity of the RNA was assessed by determining the ratio of
absorbance at 260nm to that at 280nm. The reactions were
performed with the kit Illustra Ready To Go (GE Healthcare,
Buckinghamshire, UK) in a PTC-200 thermal cycler (MJ
Research Inc., Watertown, USA). Approximately 100ng of
total RNA were required for reactions.
RT-PCR was performed initially with a step of 50◦Cf o r
30min for reverse transcription of RNA and denaturation
at 95◦C for 5min. This was followed by 35 cycles (94◦Cf o r
30sec, 57◦Cf o r3 0s e c ,a n d7 2 ◦C for 60sec; ﬁnal extension
at 72◦C for 8min). All used sense and antisense primers
are described in Table 1. Total RNA from Ntera-2.c1D1 cell
line was used as positive control of undiﬀerentiating state
of AFSCs. Human β-actin gene was used as endogenous
control in all reactions. RT-PCR products were analyzed in
2%agarosegelstainedwithethidiumbromideandvisualized
under ultraviolet light.
2.4.FlowCytometryAnalysis. Speciﬁcsurfaceproteinsofcul-
tured AFSCs were evaluated by ﬂow cytometry (FacsCalibur
cytometer, Becton Dickinson) and analyzed in CellQuest
software. 1 × 106 cells were trypsinized, washed with PBS,
a n ds t a i n e df o r1 5 m i ni nd a r kr o o mw i t hp r i m a r ya n t i -
bodies labeled with ﬂuorochromes FITC (ﬂuorescein isoth-
iocyanate): CD34, CD44, CD45, and CD90; PE (phycoery-
thrin): CD14, CD29, CD105, and appropriate isotype con-
trols (IgG-1, Invitrogen, Caltagaboratories, USA). The num-
ber of acquired events was 20,000 cells in each acquisition.
2.5. Cell Diﬀerentiation Assays. To induce osteogenic dif-
ferentiation, AFSCs at 70–80% conﬂuence were cultured
in osteogenic medium (α-MEM supplemented with 20%
FBS, 10mM glycerol phosphate, 50mM ascorbic acid, and
100nM dexamethasone) for 3 weeks. The medium was
changed twice weekly. The osteogenic diﬀerentiation was
evaluated by cell staining (Alizarin Red and von Kossa) and
RT-PCR (osteocalcin, osteopontin and Wnt-1 gene expres-
sion).
To induce adipose tissue diﬀerentiation, AFSCs were
treatedwithadipogenicmedium:α-MEMwith10−2 uMdex-
amethasone, 0.5mg/mL insulin, 200mM indomethacin and
50mM isobutilmethilxantine for 3 weeks. Medium changes
were carried out twice weekly. Presence of intracellular lipid
droplets, indicative of adipocyte diﬀerentiation, was assessed
by Oil Red O staining. PPAr-γ and lipoprotein lipase gene
expression was determined by RT-PCR.Journal of Biomedicine and Biotechnology 3
Table 1: RT-PCR primer sequences.
Gene Primers PCR products (bp) Tm (◦C)
Oct-4 5 -c g tg a ag c tg g ag a ag g ag a ag c tg- 3  
5 - caa ggg ccg cag ctt aca cat gtt c-3  247 61
Nanog 5 -cat gag tgt gga tcc agc ttg-3 
5 - c c tg a at a ag c ag a tc c at g g - 3   191 52
Osteocalcin 5 -atg aga gcc ctc aca ctc ct-3 
5  caa ggg gaa gag gaa aga ag-3  359 55
Osteopontin 5 - c a tg g ca t ca c ct g tg c ca t ac c - 3  
5 -cag tga cca gtt cat cag att cat c-3  331 57
Wnt-1 5 -cac gac act cgt gca gta cgc-3 
5 -aca gac act cgt gca gta cgc-3  233 58
Collagen 2A1 5 -cca gga cca aag gga cag aaa g-3 
5 -ttc acc agg ttc acc agg att g-3  398 57
Perlecan 5 -cat aga gac cgt cac agc aag-3 
5 -atg aac acc aca ctg aca acc-3  300 55
Syndecan 5 -cct tca cac tcc cca cac-3 
5 -ggc ata gaa ttc ctc ctg ttg-3  410 54
PPAR-γ 2 5 - g c tg t ta t gg g tg a aa c tc t g - 3  
5 -ata agg tgg aga tgc agg ctc-3  351 55
Lipoprotein lipase 5 - c a gc a aa a cc t tc at g g t - 3  
5 -agt ttt ggc acc caa ctc tca-3  72 53
β-actin 5 - t g gc a cc a ca c ct t ct a ca a tg a gc - 3  
5 -gca cag ctt ctc ctt aat gtc acg c-3  396 60
To induce chondrogenic diﬀerentiation, AFSCs were
growninα-MEM until 80% of conﬂuence was reached. Cells
were trypsinized, transferred to a conical tube, and cen-
trifugedat450xgfor10minatroomtemperature.Chondro-
genesis was induced by treating pelleted cells in conical tubes
with α-MEM medium, 10ng/mL TGF-βI (Calbiochem,
USA) and 100nM dexamethasone for 3 weeks. Chondro-
genic diﬀerentiation was assessed by hematoxylin and eosin
staining (H&E), immunoﬂuorescence against collagen type
II and RT-PCR (collagen II, perlecan, and syndecan gene
expression).
2.6. Cryopreservation. AFSCs (third passage) were frozen in
the ﬁnal concentration of 106 cells/mL in freezing medium
(α-MEM 20% FBS plus cryoprotectant), by two diﬀerent
methods. In the nonprogrammed time freezing protocol,
sampleswereplacedinafreezer(−20◦C)for20minfollowed
by −80◦C freezing for 12–16h and, ﬁnally, transferred
into liquid nitrogen (N2). Alternatively, programmed time
freezing protocol was used where samples were cooled
in a controlled-rate program (Thermo Forma Scientiﬁc,
Minneapolis, USA) of 1◦C/min at −60◦C, then 3◦C/min at
−100◦Cf o l l o w e db yl i q u i dN 2 storage. The cryoprotectants
u s e da l o n ew e r eM e 2SO (5 and 10%), glycerol (5 and 10%),
sucrose (30 and 60mM), and trehalose (60 and 100mM).
The samples were stored for 3 and 6 months. Thawing was
donequicklyinwaterbathat37◦C,andthencellviabilitywas
analyzed. Before cell plating all samples were washed with α-
MEM medium to remove residual cryoprotectant. After 80%
cellconﬂuencewasreached,Oct-4andNanogexpressionwas
evaluated by RT-PCR; CD34, CD45, CD44 (FITC), CD14,
CD29 and CD105 (PE) membrane markers were measured
by ﬂow cytometry; osteogenic and adipogenic diﬀerentia-
tions were performed and conﬁrmed by Alizarin Red and Oil
Red O staining, respectively.
2.7. Statistical Analysis. Data are expressed as mean ± SEM.
One-way or two-way analysis of variance (ANOVA) was
applied to the means to determine statistical diﬀerences be-
tween experimental groups followed by Bonferroni or Dun-
nett’stests.Diﬀerencesbetweenmeanvalueswereconsidered
signiﬁcant when P<0.05.
3. Results
3.1.AFSCsIsolationandDoublingTime. AFSCswereisolated
of 35 of 41 samples by their adherent properties in plastic
surface and appeared as colonies in the culture ﬂask. They
consisted of ﬁbroblast-like cell morphology. Doubling time
for AFSCs calculated after growth curve was 30 ± 4h
(Figure 1).
3.2. Cultured AFSCs Express Oct-4 and Nanog. Cultured
AFSCs expressed the transcription factors Oct-4 at diﬀerent
passages, as determined by RT-PCR. Oct-4 is a key marker
expressed in embryonic stem cells and cancer cells and
is responsible for the maintenance of the undiﬀerentiated
state. The homeodomain gene Nanog, present in pluripotent
human cells, was also expressed in cultured AFSCs conﬁrm-
ing the undiﬀerentiated state (Figure 2).
3.3. Phenotypic Characterization of AFSCs by Flow Cytometry.
The results obtained by ﬂow cytometry demonstrated that4 Journal of Biomedicine and Biotechnology
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Figure 1: AFSCs growth curve and doubling time. AFSCs (5,000cells/cm2) were seeded and cultivated in 46-well plates for 12 days. At
the end of each day, cells were washed, trypsinizated, and counted in hemocytometer. Each point refers to triplicate from two diﬀerent AF
samples. Cell doubling time calculated was 30 hours (±4h).
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Figure 2: Undiﬀerentiated gene expression (Oct-4 and Nanog). AFSCs total RNA was extracted from 3 diﬀerent samples by Trizol method,
gene expression evaluated by RT-PCR, and electrophoresed and visualized under ultraviolet light in 2% agarose gel stained with ethidium
bromide.
stem cells isolated from amniotic ﬂuid have a strong posi-
tivity for mesenchymal markers, such as CD29 (β-integrin),
CD44 (hyaluronic acid receptor), CD90 (Thy-1), and CD105
(endoglin), while they were negative for hematopoietic
m a r k e r ss u c ha sC D 1 4 ,C D 3 4a n dC D 4 5( l e u k o c yt ec o m m o n
antigen) (Figure 3).
3.4. Diﬀerentiation Properties of AFSCs. AFSCs were cul-
tivated in speciﬁc diﬀerentiation medium, as described,
to evaluate their plasticity and multipotency. Osteogenic
diﬀerentiation was conﬁrmed after 21 days by visualization
of the calcium deposits seen with Alizarin Red and von Kossa
staining (Figure 4). Cells also expressed typical genes found
in bone tissue such as osteopontin, osteocalcin, and Wnt-1.
Adipogenic diﬀerentiation was conﬁrmed by Oil Red
O staining. Cytoplasmic lipid droplets appeared stained in
red. They also expressed adipocytes genes as PPAr-γ and
lipoprotein lipase.
AFSCs were also able to diﬀerentiate into chondrogenic
tissue after stimulation with TGF-β I and dexamethasone
for 21 days. Histological sections from treated pellet showed
a typical structure of cartilage tissue. The presence of
collagen type II was detected by immunoﬂuorescence stain-
ing. Diﬀerentiated cells expressed genes typically found in
condroblasts, such as syndecan, perlecan and collagen type II
(Figure 4).
3.5. Cryopreservation. AFSCs viability after thawing did not
present statistical diﬀerence when compared the nonpro-
grammed and programmed time freezing protocols after 3
and 6 months storage (Figure 5).
Allevaluatedcryoprotectantspreservedthebasicfeatures
of AFSCs, as Oct-4 and Nanog genes expression (Figure 6),
surface markers (CD29, CD44, and CD105 positive; CD14,
CD34, and CD45 negative, Tables 2 and 3) and diﬀeren-
tiation multipotential after thawing (Figure 7). Although,Journal of Biomedicine and Biotechnology 5
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Figure 3: AFSCs membrane proteins were evaluated by ﬂow cytometry with CellQuest software. Acquisitions were shown in histograms.
AFSCs were positive for CD29 (98.27 ± 1.23%), CD44 (98.28 ± 1.65%), CD90 (97.69 ± 1.84%), CD105 (98.77 ± 0.64%) and were negative
for CD14 (1.78 ± 1.06%), CD34 (1.70 ± 1.14%), and CD45 (1.80 ± 0.74%). IgG1-FITC and IgG1-PE antibodies were utilized as isotype
controls. The number of acquired events was 20,000 in each acquisition.
Me2SO(5and10%)andglycerol(5and10%)showedhigher
rates of viability than the extracellular cryoprotectants, su-
crose and trehalose (Figure 8).
4. Discussion
The interest of mesenchymal stem cells in the scientiﬁc
community has arisen due to their peculiar characteristics.
Among them, the highlights are proliferative capacity and
diﬀerentiation potential [16–18]. Human amniotic ﬂuid
from second trimester of pregnancy was appointed recently
as an alternative source for MSCs [19, 20]; however, some
features, especially about cryopreservation analysis, are not
fully described. In the present study, we isolated AFSCs
and examined two freezing protocols as well as distinct
cryoprotectants which could maintain high viability and
stemness of AFSCs after cryopreservation.
Primary culture of human amniotic ﬂuid revealed the
presence of ﬁbroblast-like cells capable of adhesion and
colonies formation in plastic dish surface. These cells were
classiﬁed as mesenchymal stem cells by their characteristics,
as follows.
AFSCs doubling time (30 hours) founded was similar
with that described elsewhere [21], and this demonstrated
the high proliferative potential of these cells.
Key gene expression proﬁle, such as Oct-4 and Nanog, is
essential to determine the undiﬀerentiated stem cells status.
These genes are commonly found in pluripotent stem cells
and cancer cells [22]. Speciﬁc surface markers were investi-
gated using a panel of membrane antibodies that virtually
exclude the presence of contaminating hematopoietic cells6 Journal of Biomedicine and Biotechnology
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Figure 4: AFSCs plasticity. AFSCs were seeded in 6-well plates and cultivated with osteogenic, adipogenic, and chondrogenic inductor
medium for 3 weeks. (a) Control cells cultivated without inductor medium (magniﬁcation: 40x). (b) Osteogenic diﬀerentiation was assessed
by von Kossa (calcium deposits in black) and (c) Alizarin Red (calcium deposits in red) staining. Adipogenic diﬀerentiation was assessed by
Oil Red O staining. (d) Diﬀerentiated cells without staining (magniﬁcation: 40x), (e) diﬀerentiated cells stained by Oil Red O (cytoplasmic
lipids droplets in red, 400x). (f) Chondrogenic diﬀerentiation was conﬁrmed with H&E (magniﬁcation: 400x) (g) and immunoﬂuorescence
staining with antibodies against collagen type II (400x). (h) Osteogenic gene expression was determined by RT-PCR; products were
electrophorezed and visualized under ultraviolet light in 2% agarose gel stained with ethidium bromide (100bp molecular weight, control
(water), osteopontin [OPN], osteocalcin [OCN] and Wnt-1). (i) Typical adipogenic gene expression was determined by RT-PCR (100bp
molecular weight, control (water), PPAr-γ and lipoprotein lipase). (j) Chondrogenic gene expression was determined by RT-PCR (100bp
molecular weight, control (water), collagen type II, perlecan, and syndecan).
Table 2: After nonprogrammed freezing, AFSCs (n = 5) maintained their speciﬁc mesenchymal membrane proteins evaluated by ﬂow
cytometry (CD29, CD44, and CD105 positive; CD14, CD34, and CD45 negative). The number of acquired events was 15,000 in each acqui-
sition. Results are shown as percentage ±SEM.
Nonprogrammed CD14 PE CD34 FITC CD45 FITC CD29 PE CD44 FITC CD105 PE
Me2SO 5% 1.22 ± 0.25 0.29 ± 0.25 0.35 ± 0.16 98.30 ± 1.05 99.26 ± 0.39 99.01 ± 1.03
Me2SO 10% 1.02 ± 0.18 0.74 ± 0.22 5.80 ± 2.02 99.81 ± 0.11 99.90 ± 0.07 99.26 ± 0.36
Glycerol 5% 0.94 ± 0.44 0.44 ± 0.16 0.84 ± 0.31 99.54 ± 0.26 99.91 ± 0.06 98.92 ± 0.95
Glycerol 10% 0.87 ± 0.56 0.09 ± 0.27 0.16 ± 0.09 99.10 ± 0.33 99.09 ± 0.46 99.33 ± 0.51
Sucrose 30mM 1.06 ± 0.23 0.81 ± 0.51 1.08 ± 0.73 99.74 ± 0.04 99.69 ± 0.18 99.44 ± 0.12
Sucrose 60mM 0.95 ± 0.65 1.14 ± 0.89 3.49 ± 0.88 99.43 ± 0.25 99.57 ± 0.32 98. 26 ± 1.39
Trehalose 60mM 1.93 ± 0.26 0.36 ± 0.31 0.37 ± 0.26 99.86 ± 0.28 99.98 ± 0.01 98.24 ± 1.17
Trehalose 100mM 0.82 ± 0.72 0.48 ± 0.28 0.79 ± 0.17 99.91 ± 0.05 99.08 ± 0.74 99.54 ± 0.09Journal of Biomedicine and Biotechnology 7
0
10
20
30
40
50
60
70
80
90
100
V
i
a
b
i
l
i
t
y
 
(
%
)
Cryoprotectants
6MNP
6MP
M
5
%
M
1
0
%
G
5
%
G
1
0
%
S
3
0
 
m
M
S
6
0
 
m
M
T
6
0
 
m
M
T
1
0
0
 
m
M
6-month storage
(a)
0
10
20
30
40
50
60
70
80
90
100
3MNP
3MP
V
i
a
b
i
l
i
t
y
 
(
%
)
Cryoprotectants
M
5
%
M
1
0
%
G
5
%
G
1
0
%
S
3
0
 
m
M
S
6
0
 
m
M
T
6
0
 
m
M
T
1
0
0
 
m
M
3-month storage
(b)
Figure 5: AFSCs viability comparing nonprogrammed and programmed freezing protocols. we did not have statistic diﬀerences in AFSCs
viability when we compared the two freezing methods tested. (a) AFSCs viability after 6 months in programmed and nonprogrammed
freezing using diﬀerent cryoprotectants. (b) AFSCs viability after 3 months in programmed and nonprogrammed freezing using diﬀerent
cryoprotectants. M-Me2SO, G-glycerol, S-sucroses and T-trehalose. Means were compared by one-way ANOVA Dunnett posttest (∗P<
0.05).
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Figure 6: AFSCs were thawed, total RNA was extracted, and Oct-4 and Nanog gene expression was determined by RT-PCR in 2% agarose
gel stained with ethidium bromide after freezing with diﬀerent cryoprotectants. Human β- a c t i nw a su s e da se n d o g e n o u sc o n t r o l .M W :
100bp molecular weight; A: 5% Me2SO nonprogrammed; B: 5% Me2SO, programmed; C: 10% Me2SO, nonprogrammed; D: 10% Me2SO,
programmed; E: 5% Glycerol, nonprogrammed; F: 5% Glycerol, programmed; G: 10% Glycerol, nonprogrammed; H: 10% Glycerol,
programmed;I:30mMSucrose,nonprogrammed;J:30mMSucrose,programmed;K:60mMSucrose,nonprogrammed;L:60mMSucrose,
programmed; M: 60mM Trehalose, nonprogrammed; N: 60mM Trehalose, programmed; O: 100mM Trehalose, nonprogrammed; P:
100mM Trehalose; programmed; Q: positive control (Ntera-2.c1D1 cell line).
Table 3:Afterprogrammedfreezing,AFSCs(n = 5)maintainedtheirspeciﬁcmesenchymalmembraneproteinsevaluatedbyﬂowcytometry
(CD29,CD44,andCD105positive;CD14,CD34,andCD45negative).Thenumberofacquiredeventswas15,000ineachacquisition.Results
are shown as percentage ±SEM.
Programmed CD14 PE CD34 FITC CD45 FITC CD29 PE CD44 FITC CD105 PE
Me2SO 5% 1.88 ± 0.35 0.58 ± 0.22 0.85 ± 0.53 96.06 ± 2.61 97.03 ± 2.06 98.82 ± 1.06
Me2SO 10% 0.92 ± 0.46 0.75 ± 0.13 0.76 ± 0.44 99.67 ± 0.16 99.88 ± 0.10 99.02 ± 0.15
Glycerol 5% 0.91 ± 0.74 0.18 ± 0.08 0.39 ± 0.29 99.48 ± 0.40 99.85 ± 0.16 99.51 ± 0.17
Glycerol 10% 1.76 ± 0.96 1.07 ± 0.97 1.12 ± 1.01 99.71 ± 0.16 99.87 ± 0.08 99.11 ± 0.39
Sucrose 30mM 0.62 ± 0.48 0.22 ± 0.14 0.48 ± 0.15 99.29 ± 0.19 99.95 ± 0.03 99.65 ± 0.06
Sucrose 60mM 1.36 ± 0.08 0.96 ± 0.06 1.51 ± 0.83 99.35 ± 0.28 99.17 ± 0.66 99.02 ± 0.20
Trehalose 60mM 1.25 ± 0.41 0.31 ± 0.25 0.48 ± 0.25 97.77 ± 1.31 99.85 ± 0.11 98.90 ± 0.66
Trehalose 100mM 0.53 ± 0.88 0.46 ± 0.36 0.60 ± 0.56 99.50 ± 0.36 99.83 ± 0.18 98.94 ± 0.768 Journal of Biomedicine and Biotechnology
(a) Negative control
(c) Glycerol
(d) Sucrose (e) Trehalose
(b) Me2SO (c) Glycerol
(d) Sucrose (e) Trehalose
(b) Me2SO
Osteogenic Adipogenic
Figure7:Afterthawing,AFSCsfreezedwithdiﬀerentcryoprotectants((b)Me2SO,(c)glycerol,(d)sucrose,and(e)trehalose)werecultivated
with osteogenic and adipogenic inductor medium. Diﬀerentiation was conﬁrmed by Alizarin Red and Oil Red O staining after 21 days.
(a) Control cells without inductor. Calcium deposits appear in red. All cryoprotectants tested maintained osteogenic and adipogenic
diﬀerentiation potential of AFSCs after storage for 6 months.
andexamined proteins commonlypresentin MSCs,asCD29
(β-integrin), CD44 (hyaluronic acid receptor), CD90 (Thy-
1) and CD105 (endoglin). Data also showed the high diﬀer-
entiation potential of the AFSCs in osteogenic, adipogenic,
and chondrogenic lineages, thus conﬁrming their multipo-
tent state.
Cell cultures require cooling methods for long-time
storage, and the choice of freezing protocol used must be
done carefully to avoid cell death and, mainly, to maintain
the cell characteristics, as in this case, AFSCs proliferation
and plasticity properties [23]. With this aim our study
compared two freezing protocols: a programmed-rate cool-
ing and, a more conventional approach, nonprogrammed
time freezing, both with subsequent storage in liquid ni-
trogen.
The cooling rate is a critical step during freezing. If
coolingissuﬃcientlyslow,thecellisabletolosewaterrapidly
enough by exosmosis to concentrate the intracellular solutes
suﬃciently to eliminate supercooling and maintain the
chemical potential of intracellular water in equilibrium
with that of extracellular water. The result is that the cell
dehydratesanddoesnotfreezeintracellularly.Butifthecellis
cooled too rapidly, it is not able to lose water fast enough to
maintain equilibrium; it becomes increasingly supercooled
and eventually attains equilibrium by freezing intracellularly.
Intracellular ice formation leads to cell death [2].
It was observed that the two methods had no eﬀect
when compared with each other in cellular viability after
thawing.Therefore,anonprogrammedmethodshouldmake
cryopreservation more convenient and less costly because
the use of complex equipment for controlled-rate freezing is
avoided.
Cryoprotectantsareessentialtomaintainthecellviability
and function for storage at very low temperatures, including
for amniotic ﬂuid-derived stem cells [24, 25]. In this study,
diﬀerent cryoprotectants were tested, two intracellular com-
pounds that impair crystal ice formation inside the cells
(Me2SO and glycerol) and two extracellular agents which
improve freezing osmotic imbalance (sucrose and trehalose).
Me2SO is the most widely used cryoprotectant [21, 26],
but several studies report their potential to induce neuronal
diﬀerentiation in stem cells [5, 27]. This fact together with
their cell toxicity in room temperature led us to search for
other cryoprotectants to use for freezing AFSCs. Neuronal
diﬀerentiation promoted by Me2SO was not observed in our
study since cells were washed with α-MEM medium right
after thawing, eliminating any trace of the cryoprotectant.
Therefore, AFSCs frozen with Me2SO kept their Oct-4 and
Nanog genes expression and diﬀerentiation capacity.
Glycerol, another intracellular cryoprotectant, was com-
pared with Me2SO. Glycerol is also widely used in concentra-
tions of 5 and 10%, in cell cultures. It is described that it does
not promote cellular toxicity [28], but its action in AFSCs
cryopreservation has not been described so far. Glycerol,
both at 5 and 10% has caused lower viability than Me2SO,
but yet in acceptable rates for cell culture.
Disaccharides such as sucrose and trehalose have also
been widely used as natural cryoprotectants, as excipients
for freeze drying and as stabilizers during dehydration. The
precise mechanism by which disaccharides act to preserve
biological systems during freezing and drying is not well
understood. The fact that they do not enter in cells is the
main advantage,facilitating their removal afterthawing [29].
Sucrose and trehalose led to a low rate of AFSCs viability
and, consequently, an increase in lag phase after thawing,
maybe because these extracellular agents do not prevent the
formation of ice crystals within the cell.
All tested cryoprotectants maintained the Oct-4 and
Nanog gene expression and did not alter membrane markersJournal of Biomedicine and Biotechnology 9
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Figure 8: AFSCs viability comparing diﬀerent cryoprotectants (Me2SO, glycerol, sucrose, and trehalose) and programmed and nonpro-
grammed freezing protocols after 3 and 6 months. (a) viability in nonprogrammed method for 3 months; (b) viability in programmed
method for 3 months; (c) viability in nonprogrammed method for 6 months; (d) viability in programmed method for 6 months. 10%
Me2SO showed the higher viability rate similar to NR control in all cases. NR-AFSCs viability control measured before freezing procedure.
M-Me2SO, G-glycerol, S-sucrose, and T-trehalose. Means were compared by one-way ANOVA Dunnett’s (∗∗∗P<0.05) and Bonferroni
(#P<0,05) post tests.
or the plasticity of AFSCs post thawing, which were able to
diﬀerentiate into bone and fat tissues after thawing.
5. Conclusions
Human amniotic ﬂuid collected in the second trimester of
gestation contains mesenchymal stem cells which show a
high rate of proliferation in vitro and multipotent proﬁle,
as shown by histological and gene expression studies. Both,
nonprogrammed and programmed time freezing methods,
could be used for AFSCs cryopreservation for 6 months.
Although all tested cryoprotectants maintained Oct-4 and
Nanog gene expression, typical surface markers, and mul-
tilineage diﬀerentiation of AFSCs, only Me2SO and glycerol
presented workable viability ratio.
Conﬂict of Interests
The authors declare no conﬂict of interests.
Acknowledgments
This paper was supported by Conselho Nacional de Desen-
volvimento Cient´ ıﬁco e Tecnol´ ogico (CNPq), Financiadora
de Estudos e Projetos (FINEP), and Instituto Nacional de
Ciˆ encia e Tecnologia-Fluidos Complexos (INCT-FCx), Bra-
zil.
References
[1] J. H. Moon, J. R. Lee, B. C. Jee et al., “Successful vitriﬁcation
of human amnion-derived mesenchymal stem cells,” Human
Reproduction, vol. 23, no. 8, pp. 1760–1770, 2008.
[2] S. Ozkavukcu and E. Erdemli, “Cryopreservation: basic
knowledge and biophysical eﬀects,” Journal of Ankara Medical
School, vol. 24, no. 4, pp. 187–196, 2002.
[3] J. M. Davis, S. D. Rowley, H. G. Braine, S. Piantadosi, and G.
W. Santos, “Clinical toxicity of cryopreserved bone marrow
graft infusion,” Blood, vol. 75, no. 3, pp. 781–786, 1990.
[4] B. Neuhuber, G. Gallo, L. Howard, L. Kostura, A. Mackay, and
I. Fischer, “Reevaluation of in vitro diﬀerentiation protocols
for bone marrow stromal cells: disruption of actin cytoskele-
ton induces rapid morphological changes and mimics neu-
ronalphenotype,”JournalofNeuroscienceResearch,vol.77,no.
2, pp. 192–204, 2004.
[5] K. Mareschi, D. Rustichelli, M. Novara et al., “Neural dif-
ferentiation of human mesenchymal stem cells: evidence for
expression of neural markers and eag K+ channel types,” Ex-
perimental Hematology, vol. 34, no. 11, pp. 1563–1572, 2006.10 Journal of Biomedicine and Biotechnology
[6] A. R. Prusa, E. Marton, M. Rosner et al., “Neurogenic cells in
humanamnioticﬂuid,”AmericanJournalofObstetricsandGy-
necology, vol. 191, no. 1, pp. 309–314, 2004.
[7] D. F. Stroncek, S. K. Fautsch, L. C. Lasky, D. D. Hurd, N. K.
C. Ramsay, and J. McCullough, “Adverse reactions in patients
transfused with cryopreserved marrow,” Transfusion, vol. 31,
no. 6, pp. 521–526, 1991.
[ 8 ]R .S y m e ,M .B e w i c k ,D .S t e w a r t ,K .P o r t e r ,T .C h a d d e r t o n ,
and S. Gl¨ uck, “The role of depletion of dimethyl sulfoxide
before autografting: on hematologic recovery, side eﬀects, and
toxicity,” Biology ofBloodandMarrowTransplantation, vol.10,
no. 2, pp. 135–141, 2004.
[9] A.J.Friedenstein,U.F.Deriglasova,N.N.Kulaginaetal.,“Pre-
cursors for ﬁbroblasts in diﬀerent populations of hematopoi-
etic cells as detected by the in vitro colony assay method,”
Experimental Hematolology, vol. 2, no. 2, pp. 83–92, 1974.
[10] R. Barzilay, I. Kan, T. Ben-Zur, S. Bulvik, E. Melamed, and
D. Oﬀen, “Induction of human mesenchymal stem cells into
dopamine-producing cells with diﬀerent diﬀerentiation pro-
tocols,” Stem Cells and Development, vol. 17, no. 3, pp. 547–
554, 2008.
[11] P. Stock, S. Br¨ uckner, S. Ebensing, M. Hempel, M. M.
Dollinger, and B. Christ, “The generation of hepatocytes from
mesenchymal stem cells and engraftment into murine liver,”
Nature Protocols, vol. 5, no. 4, pp. 617–627, 2010.
[12] A. R. Prusa and M. Hengstschl¨ ager, “Amniotic ﬂuid cells and
human stem cell research: a new connection,” Medical Science
Monitor, vol. 8, no. 11, pp. 253–257, 2002.
[13] P. S. Anker, S. A. Scherjon, C. Kleijburg-van der Keur et al.,
“Amniotic ﬂuid as a novel source of mesenchymal stem cells
for therapeutic transplantation,” Blood, vol. 102, no. 4, pp.
1548–1549, 2003.
[14] D. Fauza, “Amniotic ﬂuid and placental stem cells,” Best Prac-
tice and Research, vol. 18, no. 6, pp. 877–891, 2004.
[15] A. R. Prusa, E. Marton, M. Rosner, G. Bernaschek, and M.
Hengstschl¨ ager, “Oct-4-expressing cells in human amniotic
ﬂuid: a new source for stem cell research?” Human Reproduc-
tion, vol. 18, no. 7, pp. 1489–1493, 2003.
[16] B. M. Abdallah and M. Kassem, “Human mesenchymal stem
cells: from basic biology to clinical applications,” Gene Ther-
apy, vol. 15, no. 2, pp. 109–116, 2008.
[17] C. M. Kolf, E. Cho, and R. S. Tuan, “Mesenchymal stromal
cells. Biology of adult mesenchymal stem cells: regulation of
niche, self-renewal and diﬀerentiation,” Arthritis Research and
Therapy, vol. 9, no. 1, article 204, 2007.
[18] Y.Shi,G.Hu,J.Suetal.,“Mesenchymalstemcells:anewstrat-
egy for immunosuppression and tissue repair,” Cell Research,
vol. 20, no. 5, pp. 510–518, 2010.
[19] B. Streubel, G. Martucci-Ivessa, T. Fleck, and R. E. Bittner,
“In vitro transformation of amniotic cells to muscle cells-
background and outlook,” Wien Medizinische Wochenschrift,
vol. 146, no. 9-10, pp. 216–217, 1996.
[ 2 0 ]M .S .T s a i ,J .L .L e e ,Y .J .C h a n g ,a n dS .M .H w a n g ,“ I s o l a t i o n
of human multipotent mesenchymal stem cells from second-
trimester amniotic ﬂuid using a novel two-stage culture
protocol,” Human Reproduction, vol. 19, no. 6, pp. 1450–1456,
2004.
[21] M. G. Roubelakis, K. I. Pappa, V. Bitsika et al., “Molecular
and proteomic characterization of human mesenchymal stem
cellsderivedfromamnioticﬂuid:comparisontobonemarrow
mesenchymal stem cells,” Stem Cells and Development, vol. 16,
no. 6, pp. 931–951, 2007.
[22] S. Zangrossi, M. Marabese, M. Broggini et al., “Oct-4 expres-
sion in adult human diﬀerentiated cells challenges its role as
a pure stem cell marker,” Stem Cells, vol. 25, no. 7, pp. 1675–
1680, 2007.
[23] W. X. Liu, M. J. Luo, P. Huang et al., “Comparative study
between slow freezing and vitriﬁcation of mouse embryos
using diﬀerent cryoprotectants,” Reproduction in Domestic
Animals, vol. 44, no. 5, pp. 788–791, 2009.
[24] J. McCullough, R. Haley, M. Clay, A. Hubel, B. Lindgren, and
G. Moroﬀ, “Long-term storage of peripheral blood stem cells
frozen and stored with a conventional liquid nitrogen tech-
nique compared with cells frozen and stored in a mechanical
freezer,” Transfusion, vol. 50, no. 4, pp. 808–819, 2010.
[25] J. M. Seo, M. Y. Sohn, J. S. Suh, A. Atala, J. J. Yoo, and Y.
H. Shon, “Cryopreservation of amniotic ﬂuid-derived stem
cells using natural cryoprotectants and low concentrations of
dimethylsulfoxide,” Cryobiology, vol. 62, no. 3, pp. 167–173,
2011.
[26] J. M. Miranda-Sayago, N. Fernandez-Arcas, C. Benito, A.
Reyes-Engel,J.R.Herrero,andA.Alonso,“Evaluationofalow
cost cryopreservation system on the biology of human amni-
otic ﬂuid-derived mesenchymal stromal cells,” Cryobiology.I n
press.
[27] A. Sputtek, S. Jetter, K. Hummel, and P. K¨ uhnl, “Cryopreser-
vation of peripheral blood progenitor cells: characteristics
of suitable techniques,” Beitr¨ age zur Infusionstherapie und
Transfusionsmedizin, vol. 34, pp. 79–83, 1997.
[28] F. G. Arnaud, “Cryopreservation of human platelets with
1.4M glycerol at -196◦C,” Thrombosis Research, vol. 53, no. 6,
pp. 585–594, 1989.
[29] J. P. Rodrigues, F. H. Paraguass´ u-Braga, L. Carvalho, E. Abdel-
hay, L. F. Bouzas, and L. C. Porto, “Evaluation of trehalose
and sucrose as cryoprotectants for hematopoietic stem cells of
umbilicalcordblood,”Cryobiology,vol.56,no.2,pp.144–151,
2008.